ArticleBiomaterials research2025
Synergistic Ion-Releasing Nanoparticles as a Therapeutic Platform for Modulating Adult Stem Cell Activity in Wound Healing.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preparation of Multifunctional Hydrogel Loaded with Isochlorogenic Acid A/FeGels (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles are increasingly utilized for their potential in targeted drug delivery, highlighting the need for innovative approaches to enhance therapeutic and regenerative outcomes. This study investigated zinc- and iron-ion-releasing nanoparticles (ZFNs) for their ability to simultaneously deliver zinc (Zn) and iron (Fe) ions, aimed at boosting the efficacy of human mesenchymal stem cells (hMSCs) in wound healing. Engineered for pH-sensitive degradation, ZFNs enable the controlled intracellular release of these ions following endocytosis by hMSCs. Our in vitro findings include favorable release kinetics and the absence of toxicity. We observed that dual-ion delivery via ZFNs markedly modulated the key zinc transporter gene expression and enhanced the angiogenesis- and migration-related gene expression in hMSCs. This activity correlates with the activation of mitogen-activated protein kinase and AKT signaling pathways, essential for processes such as cell migration and proliferation, thereby supporting tissue regeneration. Indeed, changes in the secretion profiles of hMSCs treated with ZFNs were found to enhance the migratory and regenerative capacities of both fibroblasts and keratinocytes. In vivo experiments confirmed that hMSCs integrated with ZFNs accelerate wound healing and upregulate the expression of essential skin barrier proteins. Collectively, these findings position ZFNs as a promising tool for enhancing stem-cell-mediated tissue regeneration, with potential widespread applications in clinical stem cell therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.